This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
BEY - Banner Image

Adverse reactions as per UK SmPC:

Gastrointestinal Disorders - Diarrhoea - Very common (≥1 in 10)

Diarrhoea was reported in 11.6 % of participants in the BEYONTTRA group compared with 7.6 % in the placebo group. The majority of events of diarrhoea were categorised as mild and resolved.

Metabolism & nutrition disorders - Gout - Very Common (≥1 in 10) 

Gout was reported in 11.2 % of participants in the BEYONTTRA group compared with 8.1 % in the placebo group. The majority of events of gout were categorised as mild to moderate and resolved.

This product is subject to additional monitoring. 

Please refer to the full UK Summary of Product Characteristics for detailed safety warnings and information.

Beyonttra (Acoramidis) UK SmPC

PP-BEY-GB-0012 | May 2025

Beyonttra MOA Content Card
Beyonttra®▼ (acoramidis) - Mode of Action (MOA)
Learn more about the Mode of Action of Beyonttra® (acoramidis)
PP-BEY-GB-0004, November 2025
    • 1
      UK Summary of Product Characteristics for BEYONTTRA (acoramidis)